Products for Research Use Only

AT9283 (lactic acid)

CAT: 0804-HY-10058Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10058Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
AT9283 lactic acid is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM) . AT9283 lactic acid inhibits growth and survival of multiple solid tumors in vitro and in vivo[1][2].
CAS Number
896466-76-5
UNSPSC
12352005
Target
Apoptosis; Aurora Kinase; Autophagy; Bcr-Abl; FLT3; JAK
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/at9283-lactic-acid.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1CC1)NC2=CNN=C2C3=NC(C=C4)=C(C=C4CN5CCOCC5)N3.O=C(O)[C@H](C)O
Molecular Formula
C22H29N7O5
Molecular Weight
471.51
References & Citations
[1]Howard S, et al. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. Journal of Medicinal Chemistry (2009), 52 (2), 379-388.|[2]Qi W, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130 (12) :2997-3005.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Abl; Aurora A; Aurora B; JAK2; JAK3
Citation 01
Front Oncol. 2021 Jun 18:11:656608.|PLoS Pathog. 2022 Jun 13;18 (6) :e1010620.|bioRxiv. 2025 February 21.|Cancers (Basel) . 2022 Mar 19;14 (6) :1575.|Harvard Medical School LINCS LIBRARY|J Adv Res. 2024 Feb:56:1-14.|Patent. US20180263995A1.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|University of Washington. 2025.